Medical Devices

With a new $40M loan, Hyperfine is set to accelerate the rollout of its Swoop® system, bringing AI-powered brain imaging directly to the patient's bedside.

Sydnexis's eye drop trial shows high efficacy in children 3-12, positioning it as a potential first-of-its-kind FDA-approved drug for myopia.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

Lifecore Biomedical secures its third major manufacturing deal in five months, signaling a strategic shift that could reshape the aesthetics supply chain.

With key trial enrollment complete, Pyxis Oncology refines its cancer drug MICVO for safety and prepares for pivotal data under a new, seasoned CEO.

With a new grant, Tessera Therapeutics is advancing its novel Gene Writing platform to engineer a scalable, single-shot cure for HIV. But can it work?

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

A Letter of Support from Siemens Healthineers validates Imaginostics' quest to revolutionize MRI with AI, aiming for earlier, more objective disease detection.

New study shows AI can match invasive methods for plaque analysis, a major step towards non-invasively predicting and preventing heart attacks.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

RenovoRx sets a key update call, juggling early RenovoCath device sales with its pivotal Phase III pancreatic cancer trial, a beacon for patients.

A brain aneurysm device successful in Europe has treated its first U.S. patient in a pivotal trial, promising to expand treatment options for thousands.

A 30-year-old breakthrough could revolutionize physics and cancer detection. Its inventor now demands a public test to prove it, alleging a cover-up.

With six top honors at a key summit, Fortis Healthcare highlights India's rapid growth as a trusted, affordable destination for advanced medical treatment.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

Two surgery centers operated by Constitution Surgery Alliance have been named among the nation's best, highlighting a trend of excellence in outpatient care.

Curia announces major upgrades to its UK sterile manufacturing and US biologics platforms, a strategic move to accelerate drug development timelines.

Endovascular Engineering's Hēlo system data, set for two major meetings, promises to validate blood return safety and reshape real-world PE care.

A new oral drug is being tested with existing therapies, offering a two-pronged attack on the glycogen buildup that defines this debilitating rare disease.